Literature DB >> 18024861

Toward progression-free survival as a primary end point in advanced colorectal cancer.

Greg Yothers.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 18024861     DOI： 10.1200/JCO.2007.13.6796

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.

Authors:  S Gill; S Berry; J Biagi; C Butts; M Buyse; E Chen; D Jonker; C Mărginean; B Samson; J Stewart; M Thirlwell; R Wong; J A Maroun
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.

Authors:  Marc Buyse; Stefan Michiels; Pierre Squifflet; Kathryn J Lucchesi; Kristoffer Hellstrand; Mats L Brune; Sylvie Castaigne; Jacob M Rowe
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

3.  Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research.

Authors:  Ina Jazić; Deborah Schrag; Daniel J Sargent; Sebastien Haneuse
Journal:  J Natl Cancer Inst       Date:  2016-07-05       Impact factor: 13.506

4.  Surrogate study endpoints in the era of cancer immunotherapy.

Authors:  Tsuyoshi Hamada; Keisuke Kosumi; Yousuke Nakai; Kazuhiko Koike
Journal:  Ann Transl Med       Date:  2018-11

5.  Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia.

Authors:  Marc Buyse; Pierre Squifflet; Kathryn J Lucchesi; Mats L Brune; Sylvie Castaigne; Jacob M Rowe
Journal:  Trials       Date:  2011-03-23       Impact factor: 2.279

Review 6.  Endpoints in advanced breast cancer: methodological aspects & clinical implications.

Authors:  Everardo D Saad
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

Review 7.  Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review.

Authors:  Katsuyuki Hotta; Katsuyuki Kiura; Yoshiro Fujiwara; Nagio Takigawa; Akiko Hisamoto; Eiki Ichihara; Masahiro Tabata; Mitsune Tanimoto
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

8.  Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.

Authors:  Inna Dabisch; Jürgen Dethling; Charalabos-Markos Dintsios; Melanie Drechsler; Daniel Kalanovic; Peter Kaskel; Frank Langer; Jörg Ruof; Thorsten Ruppert; Daniel Wirth
Journal:  Health Econ Rev       Date:  2014-01-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.